Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
8
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
8
×
new york blog main
new york top stories
regeneron pharmaceuticals
8
×
inclisiran
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cholesterol
fda
pcsk9
praluent
repatha
glaxosmithkline
new york
sanofi
the medicines co.
What
cholesterol
drug
lowering
medco
medicines
roundup
bio
fda
new
twice
wave
abbvie’s
according
aces
acquire
administration
agreed
akcea
alliance
angry
announced
anti
barbecuing
benefited
big
billion
biotech
bringing
brings
bristol
buy
calls
camping
cardiologist
cases
cash
center
centers
ceo
changing
Language
unset
Current search:
amgen
×
" national top stories "
×
" regeneron pharmaceuticals "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans